| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Accounting Officer
1 company
Brian Burkavage last filed a Form 4 in April 2025, as Chief Accounting Officer at IOBT. Brian Burkavage's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 11,500 shares of IOBT. Net of sales, the IOBT filings show accumulation of 10,000 shares.
Brian Burkavage has 5 Form 4 filings on record from May 2022 to April 2025, all as Chief Accounting Officer at IO Biotech (IOBT), 2022–2025.
The 6 reported transactions were 4 option or other derivative awards and 2 open-market purchases.
Counted by filing, the open-market trades come to 1 purchase worth about $10K and no sales.
The only open-market purchase was 10,000 shares of IOBT at an average $1.01 on November 22, 2023, about $10K. Twelve months later IOBT was down 35%.
Shares as reported in the last Form 4 for each company; the most recent is from April 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 22, 2023 | IOBT Io Biotech, Inc. | Chief Accounting Officer | Buy | 10,000 | $1.01 | $10,125.00 | +666.7% | +48.6% | -35.0% |